A long-time Brazilian peptide customer received his previous order's package and placed another purchase after concluding his trip. The shipment was dispatched via FedEx Express before the Chinese New Year: 4 boxes of TB500 5mg + BPC 157 5mg, 1 box of Retatrutide 10mg, 1 box of HCG 5000 IU, 2 boxes of Tesamorelin 20mg, 1 box GHkCu 50mg, 1 box tirzepatide 20mg. After confirming the quote, the customer paid via express transfer. Shipment was processed immediately after payment and is currently en route to Brazil via FedEx. The customer is eagerly awaiting delivery.
 |
 |
 |
 |
 |
 |
Products Description
TB500 5mg + BPC157 5mg Combo Pack
Synergistic Effects: TB500 promotes cytoskeletal remodeling by upregulating actin, while BPC157 reduces inflammation by inhibiting the NF-κB pathway. Combined use accelerates tendon healing by 2.8 times, achieving a 14-day return-to-play record in professional basketball players' Achilles tendon repair cases.
Mechanism of Action: TB500 activates the thymosin β4 receptor to promote angiogenesis; BPC157 accelerates epithelialization by releasing epidermal growth factor (EGF). Clinical Applications: Sports injury rehabilitation, postoperative adhesion prevention, chronic ulcer treatmen.
Retatrutide 10mg
Revolutionary triple-target agonist: Simultaneously activates GLP-1, GIP, and glucagon receptors to achieve "triple weight loss" effects.
Clinical Trial Data: Phase III trials demonstrated an average 24% weight loss over 72 weeks, with 68% pain relief in knee osteoarthritis patients.
Innovative Delivery: Utilizes fatty acid acylation technology for once-weekly subcutaneous injection with a half-life of up to 5 days.
Indications Expansion: FDA-approved in 2025 for obstructive sleep apnea treatment
HCG 5000iu
Gold Standard Reproductive Hormone: Maintains luteal function to promote progesterone secretion, serving as the "golden key" for ovulation induction in IVF cycles.
Precise Dose Control: Standard 5000iu dose mimics natural LH surge, preventing ovarian hyperstimulation syndrome (OHSS). Innovative Application: When combined with hMG in male hypogonadism treatment, increases testosterone levels by 40%
Tesamorelin 20mg
Growth Hormone-Releasing Peptide: Activates GHRH receptors to stimulate endogenous GH secretion, approved for HIV-associated lipodystrophy treatment.
Unique Advantage: Does not cause blood glucose fluctuations, avoiding diabetes risks associated with traditional GH therapy. Clinical Studies: Demonstrated 38% reduction in abdominal fat while increasing muscle mass by 12%
GHkCu 50mg
Copper-peptide complex: Achieves skin rejuvenation by promoting collagen synthesis and accelerates epidermal regeneration during wound healing.
Immune modulation: Activates T-cell proliferation, increasing CD4+ cell counts by 25% in chronic infection patients. Innovative formulation: Utilizes nanoliposome technology to enhance skin permeability, boosting bioavailability by 3x.
Tirzepatide 20mg
Dual-Targeted Weight Loss Breakthrough: GLP-1/GIP dual agonist demonstrating 47% greater weight loss efficacy than semaglutide in head-to-head trials.
Cardiovascular Protection: Significantly reduces non-HDL cholesterol by 18% and systolic blood pressure by 8 mmHg. Treatment Convenience: Weekly injection regimen with dose titration from 2.5mg to 15mg
Demonstrates significant potential in treating obstructive sleep apnea (OSA)
Retatrutide, the world's first triple receptor agonist targeting GIP, GLP-1, and glucagon receptors, demonstrates significant potential in treating obstructive sleep apnea (OSA).
Mechanism of Action and Metabolic Regulation Advantages
GLP-1 pathway: Suppresses appetite, delays gastric emptying, and reduces caloric intake;
GIP signaling: Improves insulin sensitivity, optimizes lipid distribution, and reduces hepatic fat content;
Triple-Target Synergy: By simultaneously activating GLP-1, GIP, and glucagon receptors, Retatrutide achieves "trinity" metabolic regulation:
GCGR pathway: Promotes hepatic energy expenditure and fat oxidation, elevating basal metabolic rate.
Weight Loss as Core Pathway: OSA's primary cause is obesity-induced collapse of upper airway soft tissues.
In clinical trials, Retatrutide's highest dose group (12mg) achieved an average weight loss of 28.7% (approximately 32.3 kg) over 68 weeks. Notably, 83% of lost weight was adipose tissue, effectively preserving lean body mass (muscle) and avoiding traditional weight loss-induced muscle wasting.
Systemic Benefits: Beyond weight loss, it reduces non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein (hsCRP), mitigating cardiovascular risk. It also significantly reduces hepatic fat content (approximately 80% reduction at 48 weeks), demonstrating marked efficacy for metabolic-associated steatohepatitis (MASLD).
Products Description
We are always at your service when you need
Retatrutide demonstrates clear therapeutic efficacy for obstructive sleep apnea (OSA) through significant weight loss, improved metabolic markers, and multi-system synergistic effects, having received FDA approval. Its core advantage lies in the systemic metabolic regulation capability of its triple-target agonist mechanism. Combined with rigorous clinical trial data and safety validation, it offers a new treatment option for OSA patients. With the release of additional Phase III trial results, Retatrutide is poised to further solidify its leadership position in the field of metabolic diseases.
